NVCT
Nuvectis Pharma IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$274.54M
P/E Ratio
—
EPS
$-1.31
Beta
-0.12
52W High
$13.34
52W Low
$5.55
50-Day MA
$9.03
200-Day MA
$7.63
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Nuvectis Pharma Inc
Nuvectis Pharma, Inc., a biopharmaceutical company, is focused on the development of targeted small molecule therapies for the treatment of cancer. The company is headquartered in Fort Lee, New Jersey.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | -154.40% |
| Return on Assets | -63.60% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.54 |
| Price-to-Book | 19.33 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -7.38 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $26.53M |
| Float | $15.47M |
| % Insiders | 41.61% |
| % Institutions | 18.23% |
Historical Volatility
HV 10-Day
99.74%
HV 20-Day
91.14%
HV 30-Day
80.78%
HV 60-Day
64.73%
HV Rank
96.4%
Volatility is currently expanding
Analyst Ratings
Consensus ($16.80 target)
2
Strong Buy3
BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026